U.S. FDA Grants BRUKINSA® (Zanubrutinib) Accelerated Approval in Relapsed or Refractory Marginal Zone Lymphoma
This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.
Hopefully the next approval will be for CLL patients, but there is still much work to be done in clinical trials to get us across that finish line.
CAR-T therapy should and will be a significant part of CLL treatment, hopefully in the not too distant future
For now, our friends with a sister B cell lymphoma, Mantle Cell Lymphoma, have reason to celebrate.
Here is the link to FDA’ s official Press Release.
Related posts